CLX - Educational Analysis * US Equities
Educational Analysis * US Equities

CLX

Earnings behavior, post-earnings drift, and the gap between consensus and the market's real expectation - the educational primer before you look at the institutional verdict.

Educational content only - not investment advice. Nothing on this page is a recommendation to buy or sell any security. Historical patterns do not predict future outcomes. Consult a licensed financial advisor before making any trading decision.
Published byGamma QC editorial
TickerCLX
CategoryEducational primer
Last reviewedNovember 9, 2026
You're viewing an older edition of this page.Read the latest edition →

Business profile & competitive position

The Clorox Company operates in the Consumer Defensive sector, specifically the Household & Personal Products industry. It is a multinational manufacturer and marketer of consumer and professional products, reporting fiscal 2026 net sales of $6.7 billion, roughly 9,200 employees, operations in approximately 25 countries, and sales into about 95 markets. Its brand portfolio spans Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, and Burt’s Bees on the consumer side, plus Purell, CloroxPro, and CloroxHealthcare on the professional side.

The company’s 9.4% net margin is consistent with a stable, branded consumer-products business that can extract value from household-name recognition. However, its ROE of -1,920.6% is not a read on operating weakness; it signals a deeply negative equity base, often produced by aggressive share repurchases that reduce book equity toward or below zero. That accounting distortion means investors should look past the headline ROE and focus on cash generation, margin stability, and brand pricing power when assessing competitive moat. The GOJO acquisition, completed in April 2026, is the most recent attempt to widen that moat by adding a leading health-and-hygiene platform and a stronger business-to-business channel.

Financial posture

Clorox currently carries a $12.6 billion market capitalization and trades at a P/E of 18.7. The 0.58 beta underlines its defensive, low-correlation profile relative to the broader equity market, which is typical for a staples name but also means the stock generally participates less aggressively in risk-on rallies. The 9.4% net margin supports that staples-like profitability story, even if the -1,920.6% ROE makes the capital-efficiency read unusually noisy.

Technically, the stock is at $104.16, well above its 50-day EMA of $90.56, with an RSI of 78.2. An RSI above 70 is conventionally viewed as overbought, so the recent move has been sharp relative to its medium-term trend. That positioning is worth keeping in context when evaluating whether post-earnings momentum has already been priced in.

Strategic priorities & outlook

Clorox’s most recent 10-K outlines an operational agenda built around its IGNITE strategy, which rests on four choices: fueling long-term profitable growth, innovating consumer experiences, reimagining how the company and its people work, and continuously evolving the product portfolio. A major near-term execution item is the completion and optimization of a new enterprise resource planning (ERP) system and broader digital transformation, intended to generate long-term efficiencies across supply chain, digital commerce, innovation, and brand building.

The company also plans to keep investing in strong brands, strategic digital capabilities, and a streamlined operating model, while advancing health and hygiene expansion and portfolio optimization. The April 2026 GOJO acquisition sits squarely in that bucket, as Clorox works to integrate the business and grow in professional and institutional markets. It is worth noting that fiscal 2026 saw declines in organic sales and earnings, with diluted EPS down 26%, partly attributed to macroeconomic headwinds and ERP transition timing that had pulled some sales into fiscal 2025. A smaller but material transition occurred on January 31, 2026, when the Glad bags and wraps venture with P&G expired, requiring Clorox to purchase P&G’s 20% interest; Glad retained core intellectual-property licenses on a royalty-free basis.

Macro & geopolitical exposure

As a Household & Personal Products company, Clorox faces macro pressures common to the sector rather than idiosyncratic to the firm. Key exposures include commodity and input costs: resins and plastics for Glad and Brita, chemicals and fragrances for cleaning products, and agricultural inputs for Kingsford and Hidden Valley. Freight, logistics, and packaging costs also flow directly through margins. Demand is defensive in nature, but not immune to trade-down pressure when households seek private-label alternatives.

The industry also carries meaningful customer-concentration risk; while this is company-specific, the broader sector’s reliance on a handful of mass retailers is a recurring feature, not a one-off. On the regulatory side, disinfectants and sanitizers draw EPA scrutiny, health-oriented formulations can involve FDA/FTC oversight, and plastic-packaging and sustainability rules increasingly affect household-product companies. With selling operations spanning about 95 markets, currency translation is a routine macro variable as well.

Recent developments

November 2026 headlines have put Clorox in a dividend-income context. On November 9, 2026, fool.com included Clorox in “3 Magnificent High-Yield Dividend Stocks to Buy Near Their 52-Week Lows,” and on November 5, 2026 the same outlet listed it among “3 High-Yielding Dividend Stocks That Investors Can Safely Buy and Hold for Decades.” Also on November 9, 2026, benzinga.com noted Clorox alongside Take-Two, ExxonMobil, and a financial stock on CNBC’s “Final Trades.” Earlier, on November 6, 2026, defenseworld.net published “Analyzing Clorox (NYSE:CLX) & Reynolds Consumer Products (NASDAQ:REYN).” Collectively, the coverage underscores market interest in CLX as a defensive income candidate and as a peer-comparison subject within household products.

Earnings behavior & post-earnings drift

Clorox has beaten earnings estimates in 6 of the last 8 quarters, a 75% beat rate, with an average earnings surprise of 11.1%. The average 5-day post-earnings price move across those quarters has been +6.63%, classified as an “up” drift. That pattern suggests the market has often needed more than the overnight session to fully process the report.

The most recent quarters show the nuance behind the averages. For the report dated November 2, 2026, CLX delivered actual EPS of $1.55 versus an estimate of $1.07 for a 44.9% positive surprise; the stock rose 4.34% the next day and 15.78% over the following five days. On August 3, 2026, a $1.66 actual versus $1.64 estimate—only a 1.2% surprise—still produced a 6.52% next-day gain and a 9.61% five-day gain. In contrast, the April 30, 2026 report showed a $1.64 actual against a $1.55 estimate (5.8% surprise), yet the stock fell 9.67% the next day and 4.49% over five days, hinting that guidance or operational commentary can override the headline beat. Even the lone miss in this window—February 3, 2026, with actual EPS of $1.39 versus $1.43 estimated (-2.8% surprise)—saw the stock rise 2.43% the next day and 5.63% over five days.

The next scheduled earnings release is February 2, 2027, after the close, with the current consensus EPS estimate at $1.07. With the stock’s RSI at 78.2 and the price already stretched above its 50-day EMA, the setup around that report will likely be watched closely by both fundamental and technical traders.

For a deeper dive, look at the full institutional verdict on CLX, which aggregates analyst ratings, price targets, and qualitative notes to complement these quantitative observations.

Frequently Asked Questions

Why is Clorox’s ROE so sharply negative?

The reported ROE of -1,920.6% reflects a negative or near-zero shareholders’ equity base, an accounting outcome that can occur when share buybacks and accumulated adjustments exceed retained earnings. It does not necessarily describe current operating performance, which is better captured by the 9.4% net margin and cash-flow metrics.

What are Clorox’s main strategic priorities?

According to its most recent 10-K, Clorox is executing its IGNITE strategy, rolling out a new ERP system and broader digital transformation, investing in brands and digital capabilities, and integrating the April 2026 GOJO acquisition to expand in health, hygiene, and professional markets.

How has Clorox stock typically reacted after earnings?

Over the last eight quarters, CLX has beaten estimates 75% of the time with an average earnings surprise of 11.1%, and the average five-day post-earnings move has been +6.63%, classified as an upward drift. Individual quarters have varied, including an April 2026 beat that was followed by a sharp next-day decline.

Real Data - Gamma QC Earnings IntelligenceAs of Nov 9, 2026
The Clorox Company · Consumer Defensive / Household & Personal Products
$12.6BMarket cap
18.7P/E
9.4%Net margin
-1920.6%ROE
75%Beat rate, last 8Q
11.1%Avg EPS surprise
6.63%Avg 5-day move after earnings
2027-02-02Next earnings
ReportedActualEstimateSurprise1D Move5D Move
2026-11-02$1.55$1.07+44.9%+4.34%+15.78%
2026-08-03$1.66$1.64+1.2%+6.52%+9.61%
2026-04-30$1.64$1.55+5.8%-9.67%-4.49%
2026-02-03$1.39$1.43-2.8%+2.43%+5.63%
2025-11-03$0.85$0.818+3.9%--
2025-07-31$2.87$2.2+30.5%--
Beyond the primer

Get the institutional verdict on CLX

Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.

Read the CLX verdict at Gamma QC
$49 Pro / $249 RIA * gammaqc.com

Verify authenticity

Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.